These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

752 related articles for article (PubMed ID: 29913983)

  • 1. A 6-months, randomised, placebo-controlled evaluation of efficacy and tolerability of a low-dose 7-day buprenorphine transdermal patch in osteoarthritis patients naïve to potent opioids.
    Breivik H; Ljosaa TM; Stengaard-Pedersen K; Persson J; Aro H; Villumsen J; Tvinnemose D
    Scand J Pain; 2010 Jul; 1(3):122-141. PubMed ID: 29913983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 microg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12-week, randomized, open-label, controlled, parallel-group noninferiority study.
    Karlsson M; Berggren AC
    Clin Ther; 2009 Mar; 31(3):503-13. PubMed ID: 19393841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is buprenorphine transdermal patch equally safe and effective in younger and elderly patients with osteoarthritis-related pain? Results of an age-group controlled study.
    Karlsson J; Söderström A; Augustini BG; Berggren AC
    Curr Med Res Opin; 2014 Apr; 30(4):575-87. PubMed ID: 24320787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
    Kivitz A; Ma C; Ahdieh H; Galer BS
    Clin Ther; 2006 Mar; 28(3):352-64. PubMed ID: 16750450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
    Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
    Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of E-OA-07 in moderate to severe symptoms of osteoarthritis: a double-blind randomized placebo-controlled study.
    Kulkarni MP; Shakeel A; Shinde BS; Rosenbloom RA
    Am J Ther; 2011; 18(2):170-7. PubMed ID: 21317618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis.
    Hale M; Tudor IC; Khanna S; Thipphawong J
    Clin Ther; 2007 May; 29(5):874-888. PubMed ID: 17697906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
    Sorge J; Sittl R
    Clin Ther; 2004 Nov; 26(11):1808-20. PubMed ID: 15639693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized clinical trial evaluating transdermal Ibuprofen for moderate to severe knee osteoarthritis.
    Varadi G; Zhu Z; Blattler T; Hosle M; Loher A; Pokorny R; Frey D; Carter SG
    Pain Physician; 2013; 16(6):E749-62. PubMed ID: 24284856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial.
    Sittl R; Griessinger N; Likar R
    Clin Ther; 2003 Jan; 25(1):150-68. PubMed ID: 12637117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transdermal buprenorphine plus oral paracetamol vs an oral codeine-paracetamol combination for osteoarthritis of hip and/or knee: a randomised trial.
    Conaghan PG; O'Brien CM; Wilson M; Schofield JP
    Osteoarthritis Cartilage; 2011 Aug; 19(8):930-8. PubMed ID: 21477658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial.
    Schnitzer TJ; Easton R; Pang S; Levinson DJ; Pixton G; Viktrup L; Davignon I; Brown MT; West CR; Verburg KM
    JAMA; 2019 Jul; 322(1):37-48. PubMed ID: 31265100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of topical diclofenac sodium gel for knee osteoarthritis in elderly and younger patients: pooled data from three randomized, double-blind, parallel-group, placebo-controlled, multicentre trials.
    Baraf HS; Gloth FM; Barthel HR; Gold MS; Altman RD
    Drugs Aging; 2011 Jan; 28(1):27-40. PubMed ID: 21174485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and tolerability of transdermal buprenorphine patches: a multicenter, prospective, open-label study in Asian patients with moderate to severe chronic musculoskeletal pain.
    Yoon DH; Bin SI; Chan SK; Chung CK; In Y; Kim H; Lichauco JJ; Mok CC; Moon YW; Ng TK; Penserga EG; Shin DA; You D; Moon H
    BMC Musculoskelet Disord; 2017 Aug; 18(1):337. PubMed ID: 28778219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buprenorphine 5, 10 and 20 μg/h transdermal patch: a review of its use in the management of chronic non-malignant pain.
    Plosker GL
    Drugs; 2011 Dec; 71(18):2491-509. PubMed ID: 22141389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined Treatment With Chondroitin Sulfate and Glucosamine Sulfate Shows No Superiority Over Placebo for Reduction of Joint Pain and Functional Impairment in Patients With Knee Osteoarthritis: A Six-Month Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Roman-Blas JA; Castañeda S; Sánchez-Pernaute O; Largo R; Herrero-Beaumont G;
    Arthritis Rheumatol; 2017 Jan; 69(1):77-85. PubMed ID: 27477804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of low-dose submicron diclofenac for the treatment of osteoarthritis pain: a 12 week, phase 3 study.
    Gibofsky A; Hochberg MC; Jaros MJ; Young CL
    Curr Med Res Opin; 2014 Sep; 30(9):1883-93. PubMed ID: 25050589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study.
    Steiner DJ; Sitar S; Wen W; Sawyerr G; Munera C; Ripa SR; Landau C
    J Pain Symptom Manage; 2011 Dec; 42(6):903-17. PubMed ID: 21945130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post hoc analysis of a randomized, double-blind, placebo-controlled efficacy and tolerability study of tramadol extended release for the treatment of osteoarthritis pain in geriatric patients.
    Vorsanger G; Xiang J; Jordan D; Farrell J
    Clin Ther; 2007; 29 Suppl():2520-35. PubMed ID: 18164919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.